A new tumorgraft panel to accelerate precision medicine in prostate cancer.

Date publication

mai 2023

Journal

Frontiers in oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LANG Hervé , Dr LINDNER Véronique , Dr MASSFELDER Thierry

Tous les auteurs :
Béraud C, Bidan N, Lassalle M, Lang H, Lindner V, Krucker C, Masliah-Planchon J, Potiron E, Lluel P, Massfelder T, Allory Y, Misseri Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37305585

Résumé

Despite the significant advances in the management of advanced prostate cancer (PCa), metastatic PCa is currently considered incurable. For further investigations in precision treatment, the development of preclinical models representing the complex prostate tumor heterogeneity are mandatory. Accordingly, we aimed to establish a resource of patient-derived xenograft (PDX) models that exemplify each phase of this multistage disease for accurate and rapid evaluation of candidate therapies.

Mots clés

PARP inhibitor, PDX, castrate-resistant prostate cancer (CRPC), genomic characteristics, metabolism, neuroendocine tumors, prostate cancer, tumor heterogeneity

Référence

Front Oncol. 2023 05 26;13:1130048